Litifilimab (anti-CLEC4C) - Primary antibody, specific to CLEC4C, Human IgG1, INHIBITOR of C-type lectin domain family 4 member C inhibitor

  • RUO
  • ≥95%(SDS-PAGE&SEC)
  • See COA
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Features and benefits
  • Host species: Human
  • Species reactivity(Reacts with): Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
Item Number
Ab182759
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab182759-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$69.90
Ab182759-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$319.90
Ab182759-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$659.90
Ab182759-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,049.90

Basic Description

Product NameLitifilimab (anti-CLEC4C) - Primary antibody, specific to CLEC4C, Human IgG1
SynonymsBDCA-2 antibody | BDCA2 antibody | Blood dendritic cell antigen 2 antibody | Blood dendritic cell antigen 2 protein antibody | C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 11 antibody | C-type (calcium dependent,
Specifications & PurityRUO, ≥95%(SDS-PAGE&SEC), See COA
Host speciesHuman
SpecificityCLEC4C
ConjugationUnconjugated
GradeRUO
Action TypeINHIBITOR
Mechanism of actionINHIBITOR of C-type lectin domain family 4 member C inhibitor
Product Description

Litifilimab (anti-CLEC4C) is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab (anti-CLEC4C) can be used for cutaneous lupus erythematosus (CLE) study.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE28.0 kDa (Light Chain) & 50.7 kDa (Heavy Chain), under reducing conditions; 204.4 kDa, under non-reducing conditions.
Purification MethodProtein A purified
FormLiquid
ConcentrationSee COA
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS2407378-48-5

Images

Litifilimab (anti-CLEC4C) (Ab182759) - ELISA
Immobilized BDCA2-ECD-his at 2.0 μg/mL can bind Litifilimab (anti-CLEC4C) (Ab182759) with the EC ₅₀ of 19.73 ng/mL.

Litifilimab (anti-CLEC4C) (Ab182759) - SEC
The purity of Litifilimab (anti-CLEC4C) (Ab182759) is more than 95% verified by HPLC.

Associated Targets(Human)

CLEC4C Tbio C-type lectin domain family 4 member C (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0607457Certificate of AnalysisJun 28, 2024 Ab182759
ZJ24F0607456Certificate of AnalysisJun 28, 2024 Ab182759
ZJ24F0607455Certificate of AnalysisJun 28, 2024 Ab182759

Related Documents

Solution Calculators